Suppr超能文献

肝移植中低温氧合灌注:随机对照试验和匹配研究的荟萃分析。

Hypothermic oxygenated perfusion in liver transplantation: a meta-analysis of randomized controlled trials and matched studies.

机构信息

Biliary Surgical Department of West China Hospital.

Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China.

出版信息

Int J Surg. 2024 Jan 1;110(1):464-477. doi: 10.1097/JS9.0000000000000784.

Abstract

BACKGROUND

Hypothermic oxygenated machine perfusion (HOPE) is a novel organ-preservation technology designed to optimize organ quality. However, the effects of HOPE on morbidity and mortality after liver transplantation remain unclear. This meta-analysis evaluated the potential benefits of HOPE in liver transplantation.

MATERIALS AND METHODS

The Embase, Web of Science, PubMed, Cochrane Library, and Scopus databases were searched for articles published up to 15 June 2023 (updated on 12 August 2023). Mean differences (MDs), risk ratios (RRs), and 95% confidence intervals were calculated.

RESULTS

Eleven studies encompassing five randomized controlled trials and six matched studies were included, with a total of 1000 patients. HOPE did not reduce the incidence of major postoperative complications (RR 0.80), primary non-function (PNF) (RR 0.54), reperfusion syndrome (RR 0.92), hepatic artery thrombosis (RR 0.92), renal replacement therapy (RR 0.98), length of hospital stay (MD, -1.38 days), 1-year recipient death (RR 0.67), or intensive care unit stay (MD, 0.19 days) after liver transplantation. HOPE reduced the incidence of biliary complications (RR 0.74), non-anastomotic biliary strictures (NAS) (RR 0.34), early allograft dysfunction (EAD) (RR 0.54), and acute rejection (RR 0.54). In addition, HOPE improved the retransplantation (RR 0.42) and 1-year graft loss rates (RR 0.38).

CONCLUSIONS

Compared with static cold storage (SCS), HOPE can reduce the incidence of biliary complications, NAS, EAD, and acute rejection and retransplantation rate after liver transplantation and improve the 1-year graft loss rate. These findings suggest that HOPE, when compared to SCS, can contribute to minimizing complications and enhancing graft survival in liver transplantation. Further research is needed to investigate long-term outcomes and confirm the promising advantages of HOPE in liver transplantation settings.

摘要

背景

低温氧合机器灌注(HOPE)是一种新型器官保存技术,旨在优化器官质量。然而,HOPE 对肝移植后发病率和死亡率的影响尚不清楚。本荟萃分析评估了 HOPE 在肝移植中的潜在益处。

材料和方法

检索 Embase、Web of Science、PubMed、Cochrane 图书馆和 Scopus 数据库,截至 2023 年 6 月 15 日(2023 年 8 月 12 日更新)发表的文章。计算均值差(MDs)、风险比(RRs)和 95%置信区间。

结果

共纳入 11 项研究,包括 5 项随机对照试验和 6 项匹配研究,共 1000 例患者。HOPE 并未降低肝移植术后主要并发症(RR 0.80)、原发性无功能(PNF)(RR 0.54)、再灌注综合征(RR 0.92)、肝动脉血栓形成(RR 0.92)、肾替代治疗(RR 0.98)、住院时间(MD,-1.38 天)、1 年受体死亡率(RR 0.67)或重症监护病房停留时间(MD,0.19 天)的发生率。HOPE 降低了胆道并发症(RR 0.74)、非吻合胆道狭窄(NAS)(RR 0.34)、早期移植物功能障碍(EAD)(RR 0.54)和急性排斥反应(RR 0.54)的发生率。此外,HOPE 提高了肝移植的再移植(RR 0.42)和 1 年移植物丢失率(RR 0.38)。

结论

与静态冷保存(SCS)相比,HOPE 可降低肝移植后胆道并发症、NAS、EAD 和急性排斥反应以及再移植率的发生率,并提高 1 年移植物丢失率。这些发现表明,与 SCS 相比,HOPE 有助于减少肝移植并发症和提高移植物存活率。需要进一步研究来调查长期结果,并确认 HOPE 在肝移植中的有前景的优势。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c1d/10793758/cb498bb73422/js9-110-464-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验